About Us

About Us

Kyttaro Therapeutics was incorporated in the US (Delaware corporation) in 2021 to commercialize technologies developed by the founders of Apceth Biopharma GmbH since 2007. The company is headquartered in New York, with research operations in Germany.

Kyttaro Therapeutics was incorporated in the US (Delaware corporation) in 2021 to commercialize technologies developed by the founders of Apceth Biopharma GmbH since 2007. The company is headquartered in New York, with research operations in Germany.
Kyttaro Therapeutics science - New York

Meet the Team

Meet the Team

manfred stangl md phd Kyttaro Therapeutics
Manfred Stangl, MD, PhD

Head of Renal and Pancreas Transplant Service, LMU Munich


michael strassmair md Kyttaro Therapeutics
Michael Strassmair, MD

Head of Hand Surgery, Starnberg Hospital


nancy j kelley Kyttaro Therapeutics
Nancy J Kelley, JD, MPP

President & CEO, Nancy J Kelley + Associates


Image
Dirk J. Evers, PhD

Managing Partner, Dr. Dirk Evers Consulting


Kate McDonough
Kate McDonough

Senior Consultant, Nancy J Kelley + Associates



Partner with us

Partner with us




Kyttaro is poised to commence clinical trials in Europe and the US for COVID-19 and GvHD applications. We invite interested partners to contact us for more details.

Kyttaro is poised to commence clinical trials in Europe and the US for COVID-19 and GvHD applications. We invite interested partners to contact us for more details.